Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial
Open accessPublished version of a preprint
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 24 of the 46 sources its claims cite were checked for support.
Abstract
Background: The first-line treatment for polycystic ovary syndrome (PCOS) is lifestyle modification. However, it is currently unknown whether digital medicine can assist patients with PCOS in maintaining a healthy lifestyle while alleviating PCOS symptoms. Objective: This study aims to evaluate the efficacy of WeChat-based digital intervention versus metformin treatment in women with PCOS and insulin resistance. Methods: A total of 80 women with PCOS and insulin resistance were recruited from an endocrinology clinic and randomly assigned to receive either a WeChat-based digital intervention (n=40, 50%) or metformin (n=40, 50%) for 12 weeks. The WeChat-based digital intervention consisted of 3 modules; a coach assisted the patients in using the intervention. The primary outcome was the change in a homeostatic model assessment for insulin resistance. At baseline and after the 12-week intervention, anthropometric parameters, menstruation frequency, sex hormone levels, metabolic factors, and body fat distribution were measured in the clinic. Furthermore, self-assessed web-based questionnaires on diet, exercise, sleep, anxiety, and depression were obtained. Results: A total of 72 participants completed the follow-up (for a 90% follow-up rate), including 35 of 40 (88%) participants from the digital intervention group and 37 of 40 (93%) participants from the metformin group. The homeostatic model assessment for insulin resistance in the digital intervention group was significantly improved after 12 weeks of treatment with a mean change of –0.93 (95% CI –1.64 to –0.23), but no statistical difference was observed between the groups (least squares mean difference –0.20; 95% CI –0.98 to 0.58; P=.62). Both digital intervention and metformin treatment significantly improved menstruation frequency (digital intervention: P<.001; metformin: P<.001) and reduced body weight (digital intervention: P<.001; metformin: P<.001) and total fat mass (digital intervention: P<.001; metformin: P<.001). Furthermore, the digital intervention had a significant advantage over metformin in improving waist circumference (least squares mean difference –1.84; 95% CI –3.44 to –0.24; P=.03), waist-to-hip ratio (least squares mean difference –0.02; 95% CI –0.03 to 0.00; P=.03), total fat mass (least squares mean difference –1.59; 95% CI –2.88 to –0.30; P=.02), and dehydroepiandrosterone sulfate (least squares mean difference –69.73; 95% CI –129.70 to –9.75; P=.02). In terms of safety, the main adverse events were sensations of hunger in the digital intervention group (2/40, 5%) and gastrointestinal adverse events in the metformin group (12/40, 30%). Conclusions: Our data suggest that digital intervention is an effective treatment option for patients with PCOS, with an efficacy comparable to that of metformin, and that it can also alleviate the negative effects of medications and make it easier and more efficient to adhere to lifestyle treatments. WeChat-based digital interventions have the potential to provide a new path for the improvement and health of women with PCOS in China. Trial Registration: ClinicalTrials.gov NCT05386706; https://clinicaltrials.gov/study/NCT05386706
Overview
CoChat Summary
TL;DR
In a 12-week randomized trial of 80 women with PCOS and insulin resistance, a WeChat-based digital lifestyle intervention was not statistically different from metformin for improving HOMA-IR, but it produced greater reductions in waist circumference, waist-to-hip ratio, total fat mass, and DHEAS. The digital intervention also had fewer adverse events than metformin, though metformin adherence was higher.
Key findings
- HOMA-IR improved significantly within the digital intervention group (mean change –0.93, 95% CI –1.64 to –0.23) and the metformin group (–1.07, 95% CI –2.04 to –0.09), with no significant between-group difference (least squares mean difference –0.20; 95% CI –0.98 to 0.58; P=.62).
- Both groups significantly improved menstruation frequency (both P<.001), body weight (both P<.001), and total fat mass (both P<.001); between-group differences were not significant for menstruation frequency (P=.91) or weight (P=.63).
- The digital intervention had a significant advantage over metformin for waist circumference (least squares mean difference –1.84 cm; 95% CI –3.44 to –0.24; P=.03), waist-to-hip ratio (–0.02; 95% CI –0.03 to 0.00; P=.03), total fat mass (–1.59 kg; 95% CI –2.88 to –0.30; P=.02), and DHEAS (–69.73 μg/dL; 95% CI –129.70 to –9.75; P=.02).
- Adverse events were less frequent with digital intervention: sensations of hunger in 2/40 (5%) and dizziness in 1/40 (3%), versus gastrointestinal adverse events in 12/40 (30%) with metformin; metformin discontinuation due to adverse events was 5% (2/40).
Methods
- Single-center, unblinded, 2-arm parallel randomized controlled trial with 1:1 allocation; 80 women with PCOS and HOMA-IR ≥1.8 were recruited from an endocrinology clinic at a tertiary affiliated hospital of Tongji University between June 21, 2022, and August 12, 2023.
- Participants received either a WeChat-based digital intervention (n=40) with 3 modules and coach support or metformin 1000 mg/day (n=40) for 12 weeks; primary outcome was change in HOMA-IR, with clinical, laboratory, body composition, and questionnaire measures at baseline and 12 weeks.
- Analysis used intention-to-treat with SPSS version 25; continuous outcomes were analyzed with ANCOVA using treatment as a fixed effect and baseline value as covariate, with P<.05 considered significant.
Limitations
- Stated by the authors: the sample was limited to insulin-resistant PCOS and does not represent all PCOS; sex hormones were not monitored during menstruation; participants were not blinded and multiple evaluations increased type 1 error risk; no formal cost evaluation was conducted; and long-term follow-up data are lacking.
- Evident from the text: the trial was single-center, relatively small (80 randomized, 72 followed up), and short-term (12 weeks), limiting generalizability and durability assessment.
- Evident from the text: adherence was lower in the digital intervention group (89%, 95% CI 83%-95%) than in the metformin group (98%, 95% CI 96%-99%; P=.003), and the exclusion of perimenopausal or menopausal women was a protocol deviation not reported in the ClinicalTrials.gov registration.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 2 Not valid · 13 Not checked · 126 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Our power analysis revealed that according to a web-based calculator (MedSci Sample Size tools), with a 30% sample loss rate, a minimum of 30 participants were required for each group to achieve a significant outcome (α=.05, power=0.90); the total sample size of the study was 60.”
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Methods > Measurements
What the sources say
- Not checked — no full text of the sourcecites [17] source
- Not checked — no full text of the sourcecites [25] source
- Disputedcites [26] sourceExperimental — accuracy not yet measured
The Statistical analysis section reports a different sample-size calculation: 20% anticipated dropout, 80% power, and 114 participants per group across three groups (342 total). Although both use α = .05, the cited paper does not report 30% loss, 90% power, or 30 participants per group. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plainn = 30- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a recent study, anthropometric indicators, including body weight, waist circumference, and fat mass, significantly improved in the web-based lifestyle intervention group compared with the control group [33].”
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Discussion > Principal Findings
What the sources say
- Supportedcites [33] source
The Abstract Results report significant improvements in body weight, waist circumference, and fat mass in the intervention group compared with the control group. The Results section, “Body Weight and Body Composition,” also reports greater weight and fat-mass loss and a greater long-term decrease in waist circumference. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Similarly, previous research showed that metformin did not significantly reduce waist circumference as much as lifestyle change did [31,32].”
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Discussion > Principal Findings
What the sources say
- Supportedcites [31] source
The Results report that waist circumference after treatment was significantly lower in the lifestyle-modification group than in the other three groups, including the metformin group (P=.001). This supports the comparative claim for the women with PCOS studied. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [32] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In previous studies, both insulin resistance status improvement and circulating insulin reduction have been shown to increase serum SHBG levels, thereby reducing the blood level of free testosterone in patients with PCOS [34,42].”
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Discussion > Principal Findings
What the sources say
- Supportedcites [34] source
The Discussion states that decreased circulating insulin and improved insulin resistance can increase serum SHBG, leading to decreased free testosterone in patients with PCOS. This directly supports the attributed claim. (LLM, conf=0.94)
- Supportedcites [42] source
The Discussion (page not supplied) states that insulin resistance and hyperinsulinemia in women with PCOS lower SHBG and raise free testosterone, and that insulin restrains SHBG production. It also reports improved insulin resistance, increased SHBG, and decreased free testosterone after the study intervention, consistent with the claim. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After the 12-week intervention, both groups exhibited substantial improvements in body measurements, including body weight, BMI, waist circumference, hip circumference, and waist-to-hip ratio.”
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Results > Overall Intervention Effect Between Groups
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
74 more claims
Create a free account to see all 158 claims and every source verdict.
- Probably not a substantial claim. 44
- It may state two separate claims as one. 44
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Apps can be a feasible means to deliver a PCOS-specific lifestyle intervention [29303435]”
From Availability and Use of Digital Technology Among Women With Polycystic Ovary Syndrome: Scoping Review (2025) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Homeostatic model assessment of insulin resistance | –0.93 (–1.64 to –0.23) | –1.07 (–2.04 to –0.09) | –0.20 (–0.98 to 0.58)”
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Results > Overall Intervention Effect Between Groups
Reported -0.2 · recomputed 0.14
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Pittsburgh Sleep Quality Index score | 6.35 (5.08-7.02) | 6.05 (5.46-7.24)”
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Results > Participant Characteristics
Reported 6.05 · recomputed 6.35
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Pittsburgh Sleep Quality Index score | 6.35 (5.08-7.02)”
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Results > Participant Characteristics
Reported 6.35 · recomputed 6.05
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Methods > Study Design and Participants
“were enrolled between June 21, 2022, and August 12, 2023”
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Results > Participant Characteristics
“The process of recruiting ran from June 2022 to May 2023”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Methods > Study Design and Participants
“were enrolled between June 21, 2022, and August 12, 2023”
§ Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial > Results > Participant Characteristics
“the follow-up assessments were completed in August 2023”
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139 · cited 1×
“A 14-item test called the HADS is used to assess an individual’s anxiety and depression levels [24].”
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234 · cited 1×
“The PSQI is a self-report assessment tool that measures sleep quality over a 30-day period [23].”
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“(Fasting blood glucose [mmol/L]×fasting insulin [mU/L])/22.5 was used to calculate the HOMA-IR levels [19].”
InfluentialToprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
International physical activity questionnaire: 12-country reliability and validity
CRAIG, C. L., MARSHALL, A. L., SJ??STR??M, M., BAUMAN, A. E., BOOTH, M. L., AINSWORTH, B. E., PRATT, M., EKELUND, U., YNGVE, A., SALLIS, J. F., et al. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000078924.61453.fb · Cited by 21,619 · cited 1×
“It provides data on the amount of time spent each week on several physical activity domains, including low, moderate, and vigorous intensity [21,22].”
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083 · cited 1×
“The PCOS guidelines recommend lifestyle interventions as the first-line treatment for PCOS (diet, exercise, sleep, and mood) [12,13].”
Criteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.003 · Cited by 1,358 · cited 1×
“PCOS is characterized by a range of heterogeneous symptoms with varying severities, including abnormal menstruation, hyperandrogenism (hirsutism or hyperandrogenemia), and ovarian dysfunction (oligo-ovulation or polycystic ovary morphology) [2].”
Karlsson, J., Persson, L.-O., Sjöström, L., & Sullivan, M. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801442 · Cited by 1,104 · cited 1×
“TFEQ-R21 is a questionnaire used to examine eating behavior [20].”
Cited by
Wright, P. J., Burts, C., Harmon, C., & Corbett, C. F. (2025) · JMIR Infodemiology · doi:10.2196/68469 · Cited by 8
“Apps can be a feasible means to deliver a PCOS-specific lifestyle intervention [29,30,34,35].”
Pan, Y., Tang, J., Lu, B., Kuang, M., Zhao, M., Liu, H., & Zhong, S. (2025) · Journal of Medical Internet Research · doi:10.2196/71075 · Cited by 9
“Digital CBT has been proposed as a promising tool for enhancing chronic disease management, with mounting evidence supporting its effectiveness in promoting health-related behavioral modifications [25-28].”
Self-citationTang, J., Song, T., Kuang, M., & Liu, H. (2025) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223251334439 · Cited by 6
Self-citationYu, B., Li, Y., Ma, C., Reinhardt, J. D., Dou, Q., Zuo, H., Yang, X., Li, M., Cai, C., Fan, Y., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04135-6 · Cited by 9
Zeng, H., Dou, Z., Zhang, Y.-N., Wang, C.-C., Xia, T., & Xu, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1676915 · Cited by 4
Self-citationZhang, T., Su, D., Li, S., & Yang, Y. (2025) · Journal of Clinical Nursing · doi:10.1111/jocn.17853 · Cited by 5
Xie, M., Qing, X., Huang, H., Xie, B., & Zhang, J. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01167-9 · Cited by 3
“Six studies [25, 28, 30, 35, 37, 44] analyzed the waist circumference of 520 patients with PCOS, and the meta-analysis showed a significantly greater reduction in waist circumference in the digital health intervention group compared to controls (SMD − 0.53, 95% CI −0.71 to −0.36, P < 0.00001, I 2 =…”
InfluentialA network meta-analysis of interventions for anxiety and depression in PCOS
Tan, Z., Li, Y., Liu, J., Hu, X. M., Su, X., & Huang, Y. (2026) · PeerJ · doi:10.7717/peerj.20744 · Cited by 2
Bridging the Gap in PCOD and PCOS Care: A Comprehensive Health & Wellness Platform
Keerthi Spandana, N., Shetty, L., Manoj, K. S., Akanksha, P., Chandas, E., & Ghosal, S. (2025) · International Journal of Multidisciplinary Research in Science, Engineering and Technology. · doi:10.15680/ijmrset.2025.0804510
Chen, H., Wang, Y., Xu, F., Huang, Z., & Chen, W. (2025) · Journal of Medical Internet Research · doi:10.2196/77709 · Cited by 1
“Randomized trials show that app-or WeChat-based lifestyle programs can reduce weight and improve metabolic or androgenic markers with effects comparable to metformin in some outcomes [22-24].”
Self-citationGłaz, M., Deska, Ł., Zysiak, S., Głaz, D., Kamińska, N., Zaguła, J., Sołtys, W., Kosmecki, C., Stronczyński, M., & Wicha, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4653
Arisha, R., Sengupta, S., Dewangan, H. K., Saeedan, A. S., Ansari, M. N., & Rashid, S. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156397
WeChat-Based Nursing Interventions in Women’s Mobile Health: Systematic Review
Xiao, J., (4631), R. L., Wu, Y., & Wu, T. (2026) · JMIR Nursing · doi:10.2196/82679 · Cited by 1
“Two studies confirmed that digitally supported lifestyle modification significantly reduced body weight and BMI, and enhanced reproductive outcomes in patients with polycystic ovary syndrome relative to standard care [36,56].”
Genetic Overlap between Depression and PCOS: Causal Links and Shared Biological Pathways
Wang, B., Xue, B., Wei, L., Song, H., Yuan, W., Niu, M., Peng, L., Li, X., Dong, W., Wu, C., et al. (2026) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0087
Medical information as a modern factor of self-medication and patient compliance
Soboleva, M. S., & Dyachenko, S. V. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/zkzr1oddpu
Komre, P., Gupta, A., Shah, K., Verma, N., Chauhan, N. S., Sahu, S., Tiwle, R., & Gupta, S. (2026) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2026.100101 · Cited by 1
MOBILE HEALTH AND PEER SUPPORT NETWORKS IN PCOS SELF-MANAGEMENT: A NARRATIVE REVIEW
Kępa, W., Kadłuczka, J., Papuga, A., Grzymek, M., Pawlucka, A., Pawłucka, K., Bury, J., Kraska, K., Potoniec, J., Sobek, A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6217
Metadata
- Authors
- Dilimulati, D., Shao, X., Wang, L., Cai, M., Zhang, Y., Lu, J., Wang, Y., Liu, H., Kuang, M., Chen, H., Zhang, M., & Qu, S.
- Affiliations
- Tongji University (CN)
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Zhang, Manna
- ORCID
- Venue
- Journal of Medical Internet Research
- Publisher
- JMIR Publications Inc.
- Published
- 2024-10-02
- Volume
- 26
- Pages
- e55883
- ISSN
- 1438-8871 (ISSN-L)
- PMC
- PMC11483258
- OpenAlex
- W4403052591
- Cited by
- 17
- References
- 52
- Citations by year
- 2026: 9 · 2025: 8
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Medical Internet Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82170861, 81970677, 81601269)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
- Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
- Keywords
- polycystic ovary syndrome, metformin, insulin resistance, lifestyle modification, menstrual frequency, body weight, waist circumference, fat mass, sex hormones, anxiety and depression, mobile health, digital medicine, HOMA-IR, body fat distribution, sleep, physical activity, diet, hirsutism
- MeSH terms
- Adult, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Metformin, Polycystic Ovary Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

